Western Pacific Region Index Medicus

Clinically and orally compatible formulation-manufactured DDX5 (p68)-targeting molecular glue FL118 products exhibit low toxicity but high efficacy against human cancer.

Author: Xiang LING ¹ ; Wenjie WU ¹ ; Li YAN ² ; Leslie CURTIN ³ ; Melanie M FARRAUTO ³ ; Sandra SEXTON ³ ; Anmbreen JAMROZE ¹ ; Changjun YU ⁴ ; Christos FOUNTZILAS ⁵ ; Dean G TANG ¹ ; Fengzhi LI ¹
Author Information

1. Department of Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, 14263, USA.
2. Department of Biostatistics & Bioinformatics, Roswell Park Comprehensive Cancer Center Buffalo, New York, 14263, USA.
3. Comparative Oncology Shared Resources, Roswell Park Comprehensive Cancer Center, Buffalo, New York, 14263, USA.
4. California Institute of Technology, Pasadena, CA, 91125, USA.
5. Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York, 14263, USA.
Publication Type:Journal Article
From: Journal of Pharmaceutical Analysis 2024;14(11):101001-101001
CountryChina
Language:English
Abstract: Image 1.